Genetic deletion of FOS inhibited tumor growth in a BCR‐ABL fusion protein kinase‐induced CML mouse model, and therefore, inhibition of high FOS expression reduced the intrinsic resistance of CML to TKI therapy (Kesarwani et al., 2017). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.